Скачать или смотреть The Only Approved Stem Cell Therapy for SCI: A Cure or a Gamble?

Is Japan's controversial "Stemirac" therapy the breakthrough we've been waiting for? In 2025, Nipro Corporation is pushing for full approval, and a new trial for CHRONIC injuries is finally underway.

In this video, we break down how this "Drug Factory" cell therapy works, why it was approved without a placebo trial, and what the new 2025 data means for people living with chronic spinal cord injuries.

🧪 In This Video We Cover:

The Controversy: Why Japan approved this therapy 7 years ahead of the West.

The Science: How Mesenchymal Stem Cells (MSCs) act as "Drug Factories" to protect nerves.

The Results: Analyzing the 12/13 improvement rate from the initial study.

2025 Update: The status of the new "Chronic" injury trial started in July 2023.

The Reality Check: Is this "Regenerative Tourism" worth the cost?

🔬 Scientific References:

Therapy: Stemirac (Honédra) by Nipro Corporation / Sapporo Medical University

Status: Conditional Approval (Japan), Full Application Submitted (2025)

Trial Focus: Acute (Initial) & Chronic (Ongoing)

Mechanism: Autologous Mesenchymal Stem Cells (MSCs)

📢 Follow the Research: If you found this breakdown helpful, please LIKE and SUBSCRIBE. I cover the latest SCI research papers and trials every week. Comment Below: Would you travel abroad for an experimental therapy like this?

#SpinalCordInjury #StemCells #Stemirac #RegenerativeMedicine #Nipro #SCIRecovery #ChronicSCI #ScienceNews